GSK Of U.K. To Put $100 Million Into R&D Center For Neuroscience Center (China)
This article was originally published in PharmAsia News
Executive SummaryU.K.-based GlaxoSmithKline plans to develop a $100 million neuroscience research center in China as a key element in its global drug-development strategy. The company's research-and-development head said the intention is to have the center be responsible for all work on neuro-degenerative diseases for treating diseases such as Alzheimer's, Parkinson's and multiple sclerosis. Moncef Sioui said GSK no longer sees China as an outsourcing and cheap-labor center, but now one capable of "different science." Several other global drug firms also are eying significant R&D investments in China. (Click here for more ) "GSK In $100 Million China Push" Financial Times (U.K.) (12/13/07)
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.